To further confirm that TR prevents or treats metabolic disorders through inhibition of NLRP3 inflammasome activation, we tested whether TR treatment inhibited the NLRP3 inflammasome activation and metainflammation in diabetic mouse models. The gene discussed is NLRP3; the disease is metabolic disease.